Effect of antibody-targeted chemotherapy with pingyangmycin on prostate cancer cells in vitro.
- Author:
Wei-zhen CHEN
1
;
Yong ZHANG
;
Chang-sheng LIANG
;
Yao XIE
;
Qin-qiao WEN
;
Xin GAO
Author Information
- Publication Type:Journal Article
- MeSH: Antibiotics, Antineoplastic; administration & dosage; pharmacology; Antibodies, Monoclonal; administration & dosage; pharmacology; Bleomycin; administration & dosage; analogs & derivatives; pharmacology; Cell Line, Tumor; Cell Survival; drug effects; Cytotoxicity, Immunologic; drug effects; immunology; Drug Delivery Systems; Humans; Immunoconjugates; administration & dosage; pharmacology; Male; Prostatic Neoplasms; immunology; pathology
- From: Journal of Southern Medical University 2008;28(3):406-408
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the effect of antibody-targeted chemotherapy against human prostate cancer LNCaP cells in vitro.
METHODSThe monoclonal antibody 7E11C5.3 against human prostate cancer was conjugated to pingyangmycin (PYM), mediated by dextran T-40, and the immunoreactivity of 7E11C5.3 was determined by indirect enzyme-linked immunosorbent assay. The bacteriostatic activity of the conjugate was determined using TTC assay, and its cytotoxicity against LNCaP cells was determined by MTT assay.
RESULTSThe 7E11C5.3:PYM molar ratio was l:54 in the conjugate, and the immunoreactivity of 7E11C5.3 was decreased by approximately 10% to 20% after conjugation. The bacteriostatic activity of conjugated PYM was 25% of that of free PYM. The 50% inhibitory doses (IC50) of 7E11C5.3-PYM conjugate and free PYM against the in vitro cultured LNCaP cells were 9.41-/+1.98 microg/ml and 29.92-/+7.88 microg/ml, respectively.
CONCLUSION7E11C5.3-PYM conjugate displays stronger cytotoxicity against anti-prostate cancer effects than free PYM.
